The American Medical Association's House of Delegates unanimously adopted a resolution introduced by The Endocrine Society calling for the standardization of testosterone assays, including increased measures of analytical accuracy by laboratory associations and education for clinicians who use the assays.
The American Medical Association’s House of Delegates unanimously adopted a resolution introduced by The Endocrine Society calling for the standardization of testosterone assays, including increased measures of analytical accuracy by laboratory associations and education for clinicians who use the assays.
Adoption of this resolution, which was co-sponsored by the American Association of Clinical Endocrinologists and the American Society of Reproductive Medicine, means that it is now AMA policy and is wholly supported by the full House of Delegates, The Endocrine Society said in a statement.
"The standardization of testosterone tests to produce measurements that are accurate, reliable, and comparable over time will benefit everyone from the scientists conducting research to the patients and their physicians who rely on the tests for diagnosis and treatment," said Kelly E. Mayo, PhD, president of The Endocrine Society. "The Society looks forward to working with the AMA and others in the medical community to encourage action needed to ensure testosterone assay standardization."
Specifically, the resolution states that the AMA:
EV/pembrolizumab under review in China for advanced urothelial carcinoma
March 28th 2024The sBLA is supported by findings from the phase 3 EV-302 trial, which showed that EV/pembrolizumab extended overall survival and progression-free survival vs platinum-based chemotherapy in patients with advanced urothelial carcinoma.
Potential code for prior authorizations on AMA CPT Editorial Panel meeting agenda
March 28th 2024"Good public and economic policy must align costs, benefits, and incentives; currently, all costs are incurred by physician practices, and all financial savings and benefits from prior authorization accrue to health insurance plans, leading to perverse incentives,” says Alex Shteynshlyuger, MD.